Best of heart failure

21 been hospitalized with heart failure in the past 12 months. Ivabradine significantly reduced the relative risk of hospital- ization for worsening HF or CV death (RRR 18%, p < 0.0001); the significance is driven mostly by a reduction of rehospitalization. HFNEF describes a heterogeneous pool of patients that make about 50% of HF patients with a unique set of patho- physiologic mechanisms. These patients are typically older with hypertension, obesity, renal failure, anemia, and atrial fibrillation and are more likely to be females. There is also a high incidence of diabetes and coronary artery disease in these patients [ 7 ]. In contrast to patients with impaired left ventricular EF, HFNEF patients have non-dilated left ven- tricular cavity size, concentric instead of eccentric left ven- tricular hypertrophy, and a normal EF [ 34 ]. It is controversial whether LV systolic function is truly normal in patients with HFNEF because EF is an imprecise measure of left ventricular systolic function. However, inva- sive conductance studies suggested from pressure–volume loops that end-systolic pressure–volume relationship is steeper or normal in HFNEF suggesting a normal systolic function. On the other hand, end-diastolic pressure–volume relationship is shifted leftward and upward indicating dia- stolic dysfunction [ 35 , 36 ]. Diastolic dysfunction is not uncommon among elderly patients estimated at about 5.6%, but only 1% has HFNEF [ 37 ]. In one study, the product of left ventricular mass index and left atrial volume has the highest predictive accuracy for HFNEF [ 38 ]. In addition to ventricular stiffness, arterial stiffness has also been suggested to contribute to HFNEF, and the combined ventricular–arterial stiffness leads to an exaggerated hypertensive response after small increases in LV end-diastolic volume [ 7 ]. 24.3 ACC/AHA Classification of Congestive Heart Failure The current ACC/AHA classification for CHF [ 3 ] is comple- mentary to the New York Heart Classification (NYHC) [ 39 ] and helps define the evolution of symptoms of patients with CHF. In addition, the ACC/AHA classification focuses on the risk factors for CHF by identifying patients who have risk factors for CHF. This classification includes four stages of CHF: Stage A: Asymptomatic patients with no left ventricular dys- function but are at risk of developing CHF including patients with coronary artery disease, hypertension, dia- betes mellitus, family history of cardiomyopathy, and the metabolic syndrome. Stage A is not represented in the NYHC. Stage B : Asymptomatic patients with left ventricular dys- function. This is equivalent to Class I of the NYHC. Stage C : Symptom ventricular dysf Class II and Clas ple in the United Stage D : Symptom Class IV of the in the United Sta 24.4 Pharma Heart Fa 24.4.1 Heart Fai Fraction Dysfunct As noted above, o nisms of HFNEF is with diastolic dysf patients with HF a HFNEF. “True” H nary artery disease, strictive cardiomyo and right-sided fail mia, thyrotoxicosis carditis, or intracar Diastolic dysfun ditions including cor lar disease, age [ 4 secondary to intrace [ 42 ], and hypertrop ARB (losartan) has but did not change l Isolated diastolic identified in 11.5% ease with the use o atrial size and N-t (NT-proBNP) appe function [ 45 ]. Also, are seen with differe Recently an algo posed by the work Cardiology [ 47 ]. In toms of HF, normal with evidence of a distensibility, and d of HFNEF if one of PCWP > 12 mmHg ing, E/E ′ > 15 by ti DopplerwithaBNP mL or BNP > 200 and LVH or atrial mal pulmonary ven 24 Evidence-Based Management of the Patient with Congestive Heart Failure 461 CHARM low-left ventricular ejection fraction trials. Circul tion. 2004;110:2618–26. 11. Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292:344–50. 12. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347:1397–402. 13. Levy D, Larson MG, Vasan RS, et al. The progression from hyper- tension to congestive heart failure. JAMA. 1996;275:1557–62. 14. Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br Heart J. 1994;72(2 Suppl):S3–9. 15. Blaufarb IS, Sonnenblick EH. The renin–angiotensin system in left ventricular remodeling. Am J Cardiol. 1996;77:8C–16C. 16. Solomon SD, Anavekar N, Skali H, et al. Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators. Influence of ejection fraction on cardiovascular outcomes in a broad spec- trum of heart failure patients. Circulation. 2005;112:3738–44. 17. Curtis JP, Sokol SI, WangY, et al. The association of left ventricu- lar ejection fraction, mortality, and cause of death in stable outpa- tients with heart failure. J Am Coll Cardiol. 2003;42:736–42. 18. Opie LH. The neuroendocrinology of congestive heart failure. Cardiovasc J S Afr. 2002;13:171–8. 19. Tousoulis D, Charakida M, Stefanadis C. Inflammation and endo- thelial dysfunction as therapeutic targets in patients with heart failure. Int J Cardiol. 2005;100:347–53. 20. Bauersachs J, Schafer A. Endothelial dysfunction in heart failure: mechanisms and therapeutic approaches. Curr Vasc Pharmacol. 2004;2:115–24. 21. Francis GS. Neurohumoral activation and progression of heart failure: hypothetical and clinical considerations. J Cardiovasc Pharmacol. 1998;32(Suppl 1):S16–21. 22. BlumA, Miller H. Pathophysiological role of cytokines in conges- tive heart failure. Annu Rev Med. 2001;52:15–27. 23. Bristow MR. Changes in myocardial and vascular receptors in heart failure. J Am Coll Cardiol. 1993;22(4 Suppl A):61A–71A. 24. Mann DL, Kent RL, Parsons B, Cooper G 4th. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992;85:790–804. 25. Mann DL. Basic mechanisms of disease progression in the failing heart: the role of excessive adrenergic drive. Prog Cardiovasc Dis. 1998;41(1 Suppl 1):1–8. 26. Nikolaidis LA, Trumble D, Hentosz T, et al. Catecholamines restore myocardial contractility in dilated cardiomyopathy at the expense of increased coronary blood flow and myocardial oxygen consumption (MvO 2 cost of catecholamines in heart failure). Eur J Heart Fail. 2004;6:409–19. 27. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of can- desartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. 1999;100:1056–64. 28. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–17. 29. Pitt B, Williams G, Remme W, et al. The EPHESUS trial: eplere- none in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther. 2001;15:79–87. 30. Goldsmith SR. Interactions between the sympathetic nervous system and the RAAS in heart failure. Curr Heart Fail Rep. 2004;1:45–50. 31. McMurray JJ, Packer M, DesaiAS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees. Angiotensin- eprilysin inhibition versus enalap l in heart fa lure. N Engl J Med. 2014;371:993–1004. 32. van de Wal RM, Voors AA, Plokker HW, van Gilst WH, van Veldhuisen DJ. New pharmacological strategies in chronic heart failure. Cardiovasc Drugs Ther. 2004;18:491–501. 33. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost- Brama A, Lerebours G, Tavazzi L, SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a ran- domised placebo-controlled study. Lancet. 2010;376(9744):875–85. 34. Aurigemma GP, Zile MR, GaaschWH. Contractile behavior of the left ventricle n dias lic heart failure with emphasis on regional systolic function. Circulation. 2006;113:296–304. 35. Baicu CF, Zile MR, Aurigemma GP, Gaasch WH. Left ventricular systolic performance, function and contractility in patients with diastolic heart failure. Circulation. 2005;111:2306–12. 36. Kawaguchi M, Hay I, F tics B, Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation. 2003;107:714–20. 37. Redfiled MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burde of systolic and diastolic ventrciular dysfunction in the community: appreciating the scope of heart failure epidemic. JAMA. 2003;289:194–202. 38. Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Left atrial volume as a morphophysiologic expression of left ventricu- lar diastolic dysfunction nd relation to cardi vascular risk bur- den. Am J Cardiol. 2002;90:1284–9. 39. Ahmed A. American College of Cardiology/American Heart Association Chronic Heart Failure Evaluation and Management guidelines: relevance to the geriatric practice. J Am Geriatr Soc. 2003;51:123–6. 40. Ewy GA. Diastolic dysfunction. J Insur Med. 2004;36:292–7. 41. de Las Fuentes L, Waggoner AD, Brown AL, Davila-Roman VG. Plasma triglyceride level is an independent predictor of altered left ventricular relaxation. J Am Soc Echocardiogr. 2005;18:1285–91. 42. Kasikcioglu HA, Karasulu L, Durgun E, Oflaz H, Kasikcioglu E, Cuhadaroglu C. Aortic elastic properties and left ventricular dia- stolic dysfunction in patients with obstructive sleep apnea. Heart Vessel. 2005;20:239–44. 43. Araujo AQ, Arteaga E, Ianni BM, Buck PC, Rabello R, Mady C. Effect of losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy. Am J Cardiol. 2005;96:1563–7. 44. Mottram PM, Short L, Baglin T, Marwick TH. Is “diastolic heart failure” a diagnosis of exclusion? Echocardiographic par meters of diastolic dysfunction in patients with heart failure and normal systolic function. Heart Lung Circ. 2003;12:127–34. 45. Lim TK, Ashrafian H, Dwivedi G, Collinson PO, Senior R. Increased left atrial volume index is an independent predic- t r of raised serum natriuretic peptide in patient with suspect d heart failure but normal left ventricular ejection fraction: impli- cation for diagnosis of diastolic heart failure. Eur J Heart Fail. 2006;8:38–45. 46. Qu P, Ding Y, Xia D, Wang H, Tian X. Variations in cardiac dia- stolic function in hypertensive patients with different left ventricu- lar geometric patterns. Hypertens Res. 2001;24(5):601–4. 47. Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Ech cardiograph Associatio s of the European Society of Cardiology. Eur Heart J. 2007;28:2539–50. 48. Morris SA, Van Swol M, Udani B. The less familiar side of heart failure: symptomatic diastolic dysfunction. J Fam Pract. 2005;54:501–11. 49. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the 24 Evidence-Based Management of the Patient with Congestive Heart Failure